Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells

Biochemical Pharmacology

Volumn 77, Issue 1, 2009, Pages 54-65

  Beurel, Eléonore ^a,b   Blivet Van Eggelpoël, Marie José ^a,b   Kornprobst, Michel ^a,b   Moritz, Sylviane ^a,b   Delelo, Roland ^a,b   Paye, François ^a,b,c   Housset, Chantal ^a,b   Desbois Mouthon, Christèle ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Apoptosis; c Jun N terminal kinase; CD95; Hepatocellular carcinoma; Lithium; SB 415286

Indexed keywords

(1,3 BENZOTHIAZOL 2 YL)[2 [2 (3 PYRIDINYL)ETHYLAMINO] 4 PYRIMIDINYL]ACETONITRILE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CAMPTOTHECIN; CASPASE 3; FAS ANTIGEN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LITHIUM; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RNA INTERFERENCE;

AMINOPHENOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELLS, CULTURED; DRUG SYNERGISM; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM; LIVER NEOPLASMS; MALEIMIDES; PROTEIN KINASE INHIBITORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 57049124808     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.026     Document Type: Article

References (69)

1. Bruix J., Hessheimer A.J., Forner A., Boix L., Vilana R., and Llovet J.M. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25 (2006) 3848-3856
2. Avila M.A., Berasain C., Sangro B., and Prieto J. New therapies for hepatocellular carcinoma. Oncogene 25 (2006) 3866-3884
3. Guicciardi M.E., and Gores G.J. Apoptosis: a mechanism of acute and chronic liver injury. Gut 54 (2005) 1024-1033
4. Eichhorst S.T. Modulation of apoptosis as a target for liver disease. Expert Opin Ther Targets 9 (2005) 83-99
5. Higaki K., Yano H., and Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol 149 (1996) 429-437
6. Ito Y., Monden M., Takeda T., Eguchi H., Umeshita K., Nagano H., et al. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer 82 (2000) 1211-1217
7. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion?. Nat Med 2 (1996) 1361-1366
8. Kim Y.S., Schwabe R.F., Qian T., Lemasters J.J., and Brenner D.A. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36 (2002) 1498-1508
9. Yamanaka T., Shiraki K., Sugimoto K., Ito T., Fujikawa K., Ito M., et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32 (2000) 482-490
10. Shin E.C., Seong Y.R., Kim C.H., Kim H., Ahn Y.S., Kim K., et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 34 (2002) 114-122
11. Ganten T.M., Haas T.L., Sykora J., Stahl H., Sprick M.R., Fas S.C., et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 Suppl. 1 (2004) S86-S96
12. Okano H., Shiraki K., Inoue H., Kawakita T., Yamanaka T., Deguchi M., et al. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab Invest 83 (2003) 1033-1043
13. Takehara T., Liu X., Fujimoto J., Friedman S.L., and Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34 (2001) 55-61
14. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31 (2000) 1080-1085
15. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., and Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406 (2000) 86-90
16. Schwabe R.F., and Brenner D.A. Role of glycogen synthase kinase-3 in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 283 (2002) G204-G211
17. Song L., Zhou T., and Jope R.S. Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci 5 (2004) 20
18. Liao X., Zhang L., Thrasher J.B., Du J., and Li B. Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther 2 (2003) 1215-1222
19. Rottmann S., Wang Y., Nasoff M., Deveraux Q.L., and Quon K.C. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A 102 (2005) 15195-15200
20. Lakehal F., Wendum D., Barbu V., Becquemont L., Poupon R., Balladur P., et al. Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium. Hepatology 30 (1999) 1498-1506
21. Desbois-Mouthon C., Cadoret A., Blivet-Van Eggelpoel M.J., Bertrand F., Cherqui G., Perret C., et al. Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20 (2001) 252-259
22. Martinez L.A., Naguibneva I., Lehrmann H., Vervisch A., Tchenio T., Lozano G., et al. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A 99 (2002) 14849-14854
23. Dunphy E.J., Redman R.A., Herweijer H., and Cripe T.P. Reciprocal enhancement of gene transfer by combinatorial adenovirus transduction and plasmid DNA transfection in vitro and in vivo. Hum Gene Ther 10 (1999) 2407-2417
24. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93 (1996) 8455-8459
25. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7 (2000) 793-803
26. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188 (1998) 2033-2045
27. Hao C., Song J.H., Hsi B., Lewis J., Song D.K., Petruk K.C., et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64 (2004) 8502-8506
28. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7 (2001) 383-385
29. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Buchler P., Haas T.L., et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12 (2006) 2640-2646
30. Quiroz J.A., Gould T.D., and Manji H.K. Molecular effects of lithium. Mol Interv 4 (2004) 259-272
31. Asakuma J., Sumitomo M., Asano T., and Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63 (2003) 1365-1370
32. Pespeni M.H., Hodnett M., Abayasiriwardana K.S., Roux J., Howard M., Broaddus V.C., et al. Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res 67 (2007) 2865-2871
33. Han H., Shin S.W., Seo C.Y., Kwon H.C., Han J.Y., Kim I.H., et al. 15-Deoxy-delta 12,14-prostaglandin J2 (15d-PGJ 2) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation. Apoptosis 12 (2007) 2101-2114
34. He Q., Huang Y., and Sheikh M.S. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 23 (2004) 2554-2558
35. Shankar S., and Srivastava R.K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 7 (2004) 139-156
36. Inoue H., Shiraki K., Murata K., Sugimoto K., Kawakita T., Yamaguchi Y., et al. Adenoviral-mediated transfer of p53 gene enhances TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 14 (2004) 271-275
37. Hu H., Jiang C., Schuster T., Li G.X., Daniel P.T., and Lu J. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol Cancer Ther 5 (2006) 1873-1882
38. McKee C.M., Ye Y., and Richburg J.H. Testicular germ cell sensitivity to TRAIL-induced apoptosis is dependent upon p53 expression and is synergistically enhanced by DR5 agonistic antibody treatment. Apoptosis 11 (2006) 2237-2250
39. Secchiero P., Zerbinati C., di Iasio M.G., Melloni E., Tiribelli M., Grill V., et al. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8 (2007) 395-403
40. Pluquet O., Qu L.K., Baltzis D., and Koromilas A.E. Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3beta. Mol Cell Biol 25 (2005) 9392-9405
41. Kulikov R., Boehme K.A., and Blattner C. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 25 (2005) 7170-7180
42. Watcharasit P., Bijur G.N., Song L., Zhu J., Chen X., and Jope R.S. Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 278 (2003) 48872-48879
43. Nakshatri H., Rice S.E., and Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23 (2004) 7330-7344
44. Ammirante M., Di Giacomo R., De Martino L., Rosati A., Festa M., Gentilella A., et al. 1-Methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin. Cancer Res 66 (2006) 4385-4393
45. Sah N.K., Munshi A., Kurland J.F., McDonnell T.J., Su B., and Meyn R.E. Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem 278 (2003) 20593-20602
46. Vivo C., Liu W., and Broaddus V.C. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 278 (2003) 25461-25467
47. Kim J.W., Lee J.E., Kim M.J., Cho E.G., Cho S.G., and Choi E.J. Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem 278 (2003) 13995-14001
48. Yuan P., Chen G., and Manji H.K. Lithium activates the c-Jun NH2-terminal kinases in vitro and in the CNS in vivo. J Neurochem 73 (1999) 2299-2309
49. Liu S., Yu S., Hasegawa Y., Lapushin R., Xu H.J., Woodgett J.R., et al. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem 279 (2004) 51075-51081
50. Gaillard P., Jeanclaude-Etter I., Ardissone V., Arkinstall S., Cambet Y., Camps M., et al. Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase. J Med Chem 48 (2005) 4596-4607
51. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98 (2001) 13681-13686
52. Rowinsky E.K. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23 (2005) 9394-9407
53. Oldenhuis C., Stegehuis J., Walenkamp A., de Jong S., and de Vries E. Targeting TRAIL death receptors. Curr Opin Pharmacol 8 (2008) 433-439
54. Malhi H., and Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 134 (2008) 1641-1654
55. Beurel E., and Jope R.S. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem 283 (2008) 21934-21944
56. Jope R.S., Yuskaitis C.J., and Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32 (2007) 577-595
57. Inoue S., Twiddy D., Dyer M.J., and Cohen G.M. Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ 13 (2006) 2160-2162
58. Kim J.Y., Kim Y.H., Chang I., Kim S., Pak Y.K., Oh B.H., et al. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis. Oncogene 21 (2002) 3139-3148
59. Czaja M.J. The future of GI and liver research: editorial perspectives. III. JNK/AP-1 regulation of hepatocyte death. Am J Physiol Gastrointest Liver Physiol 284 (2003) G875-G879
60. Higuchi H., Grambihler A., Canbay A., Bronk S.F., and Gores G.J. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 279 (2004) 51-60
61. Bae M.A., and Song B.J. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 63 (2003) 401-408
62. Gunawan B.K., Liu Z.X., Han D., Hanawa N., Gaarde W.A., and Kaplowitz N. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 131 (2006) 165-178
63. Behrens A., Sibilia M., and Wagner E.F. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet 21 (1999) 326-329
64. Liedtke C., Plumpe J., Kubicka S., Bradham C.A., Manns M.P., Brenner D.A., et al. Jun kinase modulates tumor necrosis factor-dependent apoptosis in liver cells. Hepatology 36 (2002) 315-325
65. Aderca I., Moser C.D., Veerasamy M., Bani-Hani A.H., Bonilla-Guerrero R., Ahmed K., et al. The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX. J Hepatol 49 (2008) 373-383
66. Beurel E., and Jope R.S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79 (2006) 173-189
67. Jope R.S., and Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7 (2006) 1421-1434
68. Henriksen E.J., and Dokken B.B. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 7 (2006) 1435-1441
69. Beurel E., Kornprobst M., Blivet-Van Eggelpoel M.J., Cadoret A., Capeau J., and Desbois-Mouthon C. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis. Int J Oncol 27 (2005) 215-222